Identifying aberrant pathways through integrated analysis of knowledge in pharmacogenomics

MOTIVATION Many complex diseases are the result of abnormal pathway functions instead of single abnormalities. Disease diagnosis and intervention strategies must target these pathways while minimizing the interference with normal physiological processes. Large-scale identification of disease pathways and chemicals that may be used to perturb them requires the integration of information about drugs, genes, diseases and pathways. This information is currently distributed over several pharmacogenomics databases. An integrated analysis of the information in these databases can reveal disease pathways and facilitate novel biomedical analyses. RESULTS We demonstrate how to integrate pharmacogenomics databases through integration of the biomedical ontologies that are used as meta-data in these databases. The additional background knowledge in these ontologies can then be used to enable novel analyses. We identify disease pathways using a novel multi-ontology enrichment analysis over the Human Disease Ontology, and we identify significant associations between chemicals and pathways using an enrichment analysis over a chemical ontology. The drug-pathway and disease-pathway associations are a valuable resource for research in disease and drug mechanisms and can be used to improve computational drug repurposing. AVAILABILITY http://pharmgkb-owl.googlecode.com

[1]  William Lewis,et al.  Combined Antiretroviral Therapy Causes Cardiomyopathy and Elevates Plasma Lactate in Transgenic AIDS Mice , 2001, Laboratory Investigation.

[2]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[3]  Sean Bechhofer,et al.  Igniting the OWL 1.1 Touch Paper: The OWL API , 2007, OWLED.

[4]  Russ B. Altman,et al.  Integration and publication of heterogeneous text-mined relationships on the Semantic Web , 2011, J. Biomed. Semant..

[5]  R. Altman,et al.  Databases in the area of pharmacogenetics , 2011, Human mutation.

[6]  Paul N. Schofield,et al.  PhenomeNET: a whole-phenome approach to disease gene discovery , 2011, Nucleic acids research.

[7]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2011 , 2010, Nucleic Acids Res..

[8]  H. Omar,et al.  Caffeine Use: Association with Nicotine Use, Aggression, and Other Psychopathology in Psychiatric and Pediatric Outpatient Adolescents , 2008, TheScientificWorldJournal.

[9]  Bernardo Cuenca Grau,et al.  OWL 2 Web Ontology Language: Profiles , 2009 .

[10]  L H Yang,et al.  Vasomodulatory action of clopidogrel and ticlopidine. , 1997, Thrombosis research.

[11]  Eric J. Arts,et al.  3′-Azido-3′-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants , 1998, Journal of Virology.

[12]  P. Robinson,et al.  The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. , 2008, American journal of human genetics.

[13]  Kei-Hoi Cheung,et al.  BioPAX – A community standard for pathway data sharing , 2010, Nature Biotechnology.

[14]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[15]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Yuji Zhang,et al.  Identification of aberrant pathways and network activities from high-throughput data , 2012, Briefings Bioinform..

[17]  Olivier Bodenreider,et al.  The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..

[18]  Jennifer E. Chubb,et al.  DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling , 2005, Science.

[19]  Erhard Rahm,et al.  FUNC: a package for detecting significant associations between gene sets and ontological annotations , 2007, BMC Bioinformatics.

[20]  Peter F. Patel-Schneider,et al.  OWL 2 Web Ontology Language , 2009 .

[21]  Markus Krötzsch,et al.  Unchain My EL Reasoner , 2011, Description Logics.

[22]  G. Weverling,et al.  Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. , 1994, The Journal of infectious diseases.

[23]  J. Herbert,et al.  Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  Russ B. Altman,et al.  Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.

[25]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2013 , 2012, Nucleic Acids Res..

[26]  Michel Dumontier,et al.  Interoperability between Biomedical Ontologies through Relation Expansion, Upper-Level Ontologies and Automatic Reasoning , 2011, PloS one.

[27]  Michel Dumontier,et al.  Integrating systems biology models and biomedical ontologies , 2011, BMC Systems Biology.

[28]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[29]  José L. V. Mejino,et al.  A reference ontology for biomedical informatics: the Foundational Model of Anatomy , 2003, J. Biomed. Informatics.

[30]  W. Kibbe,et al.  Annotating the human genome with Disease Ontology , 2009, BMC Genomics.

[31]  R. Sherer,et al.  Management of the adverse effects of antiretroviral therapy and medication adherence. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  H Britt,et al.  A new drug classification for computer systems: the ATC extension code. , 1995, International journal of bio-medical computing.

[33]  John M. Hancock,et al.  Using ontologies to describe mouse phenotypes , 2004, Genome Biology.

[34]  J. Herbert,et al.  The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A , 1994, Thrombosis and Haemostasis.

[35]  Michael Darsow,et al.  ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..

[36]  Michel Dumontier,et al.  A common layer of interoperability for biomedical ontologies based on OWL EL , 2011, Bioinform..

[37]  Mark A. Musen,et al.  Enabling enrichment analysis with the Human Disease Ontology , 2011, J. Biomed. Informatics.

[38]  S. Mohapatra,et al.  : DISEASE ONTOLOGY , 2014 .

[39]  M. Ashburner,et al.  An ontology for cell types , 2005, Genome Biology.

[40]  Zhen Zhang,et al.  Integrative Network Analysis to Identify Aberrant Pathway Networks in Ovarian Cancer , 2011, Pacific Symposium on Biocomputing.

[41]  John D. Osborne,et al.  Annotating the human genome with Disease , 2009 .

[42]  Eric J. Topol,et al.  Scientific and therapeutic advances in antiplatelet therapy , 2003, Nature Reviews Drug Discovery.